Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

FDA accepts Telix’s NDA for prostate cancer imaging agent

FDA has accepted the filing of Telix Pharmaceuticals Limited’s New Drug Application for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer.

July 26, 2024

Vol.50 No.30

Clinical Roundup

Nubeqa + androgen deprivation therapy improves rPFS for mHSPC in phase III trial

The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, research suggests, which could contribute to higher rates of aggressive prostate cancer in African American men.

July 19, 2024

Vol.50 No.29

Clinical Roundup

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.

July 19, 2024

Vol.50 No.29

In Brief

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant from NCI to advance their work in personalizing cancer treatment.

July 12, 2024

Vol.50 No.28

Drugs & Targets

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

FDA granted Fast Track designation for Ac-FL-020, a radiopharmaceutical which targets prostate-specific membrane antigen for the treatment of metastatic castration-resistant prostate cancer.xxx:more

July 12, 2024

Vol.50 No.28

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

YOU MAY BE INTERESTED IN

FDA accepts Telix’s NDA for prostate cancer imaging agent

Nubeqa + androgen deprivation therapy improves rPFS for mHSPC in phase III trial

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

Renew today!

Subscriber content

Login